专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20160361359A1 METHOD OF ENGINEERING CHEMOTHERAPY DRUG RESISTANT T-CELLS FOR IMMUNOTHERAPY 审中-公开
标题翻译：工程化疗药物耐药T细胞免疫治疗方法
公开(公告)号：US20160361359A1
公开(公告)日：2016-12-15
申请号：US15037988
申请日：2014-11-21
申请人： CELLECTIS
发明人： Julien VALTON , Philippe DUCHATEAU , David SOURDIVE
IPC分类号： A61K35/17 , C12N5/0783 , A61K31/7076
摘要： The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic T-cell resistant to chemotherapeutic agents. The therapeutic benefits afforded by this strategy should be enhanced by the synergistic effects between chemotherapy and immunotherapy. In particular, the present invention relates to a method for modifying T-cells by inactivating at least one gene encoding T-cell receptor component and by modifying said T-cells to confer drug resistance. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.
摘要翻译：本发明涉及“现成”同种异体治疗性细胞用于免疫治疗与化疗联合治疗癌症患者的用途。特别地，本发明人开发了一种对化疗药物耐药的同种异体T细胞的方法。通过化学疗法和免疫治疗之间的协同效应，可以提高该策略提供的治疗效果。特别地，本发明涉及通过使至少一种编码T细胞受体成分的基因失活并通过修饰所述T细胞以赋予耐药性来修饰T细胞的方法。本发明开启了治疗癌症的标准和负担得起的过继免疫治疗策略的方法。

62. 发明申请

US20160355875A1 METHODS AND KITS FOR DETECTING NUCLEIC ACID SEQUENCES OF INTEREST USING DNA-BINDING PROTEIN DOMAIN 审中-公开
标题翻译：检测利用DNA结合蛋白质域的核酸序列的方法和试剂盒
公开(公告)号：US20160355875A1
公开(公告)日：2016-12-08
申请号：US15028644
申请日：2014-10-10
申请人： CELLECTIS
发明人： Julien VALTON , Alexandre JUILLERAT , Fayza DABOUSSI , Marine BEURDELEY , Claudia BERTONATI , Philippe DUCHATEAU
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： C12Q1/6816 , C12Q1/6806 , C12Q1/6827 , C12Q1/6841 , G01N33/5308 , C12Q2522/101 , C12Q2565/531
摘要： The present invention relates to a method for the detection of a specific nucleic acid. Specifically, the invention provides a method and kits for detecting the presence of a specific nucleic acid using engineered DNA-binding domains such as Transcription Activator Like-Effector (TALE) domain or modular base-per-base binding domains (MBBBD). The method of the invention is particularly useful for in vitro diagnostic application.
摘要翻译：本发明涉及用于检测特定核酸的方法。具体地，本发明提供了使用工程化的DNA结合结构域如转录激活子效应（TALE）结构域或模块化碱基结合结构域（MBBBD）来检测特异性核酸的存在的方法和试剂盒。本发明的方法对于体外诊断应用特别有用。

63. 发明申请

US20160138047A1 IMPROVED POLYNUCLEOTIDE SEQUENCES ENCODING TALE REPEATS 审中-公开
标题翻译：改进多核苷酸序列编码TALE REPEATS
公开(公告)号：US20160138047A1
公开(公告)日：2016-05-19
申请号：US14898148
申请日：2014-06-13
申请人： CELLECTIS
发明人： Philippe DUCHATEAU , Sylvain ARNOULD , Julianne SMITH
IPC分类号： C12N15/90 , C12N15/86 , C12N7/00 , C12N9/22 , C07K14/00
CPC分类号： C12N15/86 , C07K14/00 , C07K2319/80 , C12N7/00 , C12N9/22 , C12N2740/15043 , C12Y301/21004
摘要： The present invention is in the field of the gene editing molecular tools. The present invention relates to rewritten nucleic acid sequences encoding repeated DNA recognition motifs of TALE (Transcription Activator-Like Effector) proteins. These nucleic acid sequences allow assembly and cloning of TALE repeats in any type of vectors, especially viral vectors. The invention thereby contributes to improving gene targeting in cells using TALE derived proteins, in particular for genetic regulation or modification. The present invention is particularly drawn to virus mediated transformation methods, by providing vectors, compositions and kits including said new nucleic acid sequences.
摘要翻译：本发明是在基因编辑领域的分子工具。本发明涉及编码TALE（转录激活子样效应物）蛋白的重复DNA识别基序的重写核酸序列。这些核酸序列允许在任何类型的载体，特别是病毒载体中组装和克隆TALE重复。因此，本发明有助于使用TALE衍生的蛋白质改善细胞中的基因靶向，特别是用于遗传调控或修饰。通过提供载体，组合物和试剂盒，包括所述新的核酸序列，本发明特别地涉及病毒介导的转化方法。

64. 发明申请

US20160122774A1 A METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY 审中-公开
标题翻译：使用CAS9 NICKASE活性生产精细DNA清除的方法
公开(公告)号：US20160122774A1
公开(公告)日：2016-05-05
申请号：US14892743
申请日：2014-05-28
申请人： CELLECTIS
发明人： Philippe DUCHATEAU , Claudia BERTONATI
IPC分类号： C12N15/82 , C12N15/90
CPC分类号： C12N15/8213 , C12N15/10 , C12N15/907 , C12Q1/683 , C12Q2521/307
摘要： The present invention is in the field of a method for genome engineering based on the type II CRISPR system, particularly a method for improving specificity and reducing potential off-site. The method is based on the use of nickase architectures of Cas9 and single or multiple crRNA(s) harboring two different targets lowering the risk of producing off-site cleavage. The present invention also relates to polypeptides, polynucleotides, vectors, compositions, therapeutic applications related to the method described here.
摘要翻译：本发明在基于II型CRISPR系统的基因组工程方法的领域中，特别是一种提高特异性并降低非局部潜在能力的方法。该方法基于使用Cas9的切口结构和含有两个不同靶标的单个或多个crRNA，其降低产生场外切割的风险。本发明还涉及与这里描述的方法相关的多肽，多核苷酸，载体，组合物，治疗应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式